GlassScriptPhysician profile
Spencer Boyle
NPI 1093341950
$2,377.15
in general payments reported to CMS, 2019-2025
11 companies · $652 in 2025
The $652 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $34.12 · 2023: $1,077 · 2024: $615 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,543 · Grant: $800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,543.03 |
| Grant | $800.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,309.46 | 2023-2025 | |
| Biocryst US Sales Co., LLC | $280.60 | 2025 | Orladeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $193.05 | 2024 | Cuvitru, Hyqvia |
| Grifols USA, LLC | $167.42 | 2024 | Xembify |
| Pharming Healthcare, INC. | $133.85 | 2023-2025 | Joenja, Ruconest |
| Amgen INC. | $119.83 | 2024 | Actimmune |
| Glaxosmithkline, LLC. | $61.40 | 2025 | Nucala |
| Pfizer INC. | $34.12 | 2020 | |
| Novartis Pharmaceuticals Corporation | $29.75 | 2025 | |
| Incyte Corporation | $27.81 | 2025 | Opzelura |
| Ionis Pharmaceuticals, INC. | $19.86 | 2025 | Dawnzera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Spencer Boyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.